With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...
The most recent earnings announcement Circassia Pharmaceuticals Plc’s (LSE:CIR) released in December 2017 indicated that losses became smaller relative to the prrior year’s level – great news for ...
Add Yahoo as a preferred source to see more of our stories on Google. LONDON (Reuters) - Circassia Pharmaceuticals (CIRCI.L), a British company developing allergy therapies, said on Friday it had ...
UK biotech Circassia has finally given up on its allergy drug development business, citing difficulties in overcoming a strong placebo effect in the trials required for approval by regulators. After a ...
The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...
OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell ...
LONDON (Reuters) - Britain's Circassia Pharmaceuticals (CIRCI.L) is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader ...
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune® cat allergy treatment for cat ...
Oxford, UK - 8 December 2014: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces results from a phase IIb ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in UK pharma group Circassia jumped almost 10 per cent on Thursday morning after its partner AstraZeneca ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Losses at UK drugmaker Circassia Pharmaceuticals widened further than expected in 2016, after the failure of a ...
LONDON (Reuters) - Circassia Pharmaceuticals, a British company developing allergy therapies, said on Friday it had agreed to buy Sweden's Aerocrine and privately held Prosonix, two companies focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results